CYP2C19基因多态性及非遗传因素对东亚冠心病患者氯吡格雷血小板抑制作用的影响 - Suppr

The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.

作者信息

Amin Arwa M, Sheau Chin Lim, Mohamed Noor Dzul Azri, Mostafa Hamza, Abdul Kader Muhamad Ali S K, Kah Hay Yuen, Ibrahim Baharudin

机构信息

School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.

出版信息

Thromb Res. 2017 Oct;158:22-24. doi: 10.1016/j.thromres.2017.07.032. Epub 2017 Aug 1.

DOI:10.1016/j.thromres.2017.07.032

PMID:28802144

Abstract

摘要

相似文献

The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.

Thromb Res. 2017 Oct;158:22-24. doi: 10.1016/j.thromres.2017.07.032. Epub 2017 Aug 1.

Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.

Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26.

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.

Braz J Med Biol Res. 2017 Jan 9;50(1):e5660. doi: 10.1590/1414-431X20165660.

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.

PLoS One. 2014 Oct 16;9(10):e110188. doi: 10.1371/journal.pone.0110188. eCollection 2014.

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.

Chin Med J (Engl). 2015 Aug 20;128(16):2183-8. doi: 10.4103/0366-6999.162515.

Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity.

Thromb Res. 2014 Oct;134(4):877-83. doi: 10.1016/j.thromres.2014.07.018. Epub 2014 Aug 14.

Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.

J Thromb Thrombolysis. 2015 Oct;40(3):288-93. doi: 10.1007/s11239-015-1173-y.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.

Am J Ther. 2015 May-Jun;22(3):222-30. doi: 10.1097/MJT.0000000000000125.

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

Thromb Res. 2011 Jan;127(1):23-8. doi: 10.1016/j.thromres.2010.10.021.

引用本文的文献

Prevalence of clopidogrel resistance in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Postepy Kardiol Interwencyjnej. 2025 Jun 5;21(2):259-261. doi: 10.5114/aic.2025.151854. eCollection 2025 Jun.

The Frequency of Gene Polymorphisms in Burkina Faso Patients Treated with Clopidogrel.

Appl Clin Genet. 2025 May 1;18:55-61. doi: 10.2147/TACG.S509095. eCollection 2025.

METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients.

Open Med (Wars). 2024 Feb 7;19(1):20240899. doi: 10.1515/med-2024-0899. eCollection 2024.

The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.

Cardiovasc Drugs Ther. 2025 Apr;39(2):347-356. doi: 10.1007/s10557-024-07544-6. Epub 2024 Jan 15.

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention.

Front Cardiovasc Med. 2023 Feb 8;9:1027892. doi: 10.3389/fcvm.2022.1027892. eCollection 2022.

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).

Molecules. 2021 Apr 1;26(7):1987. doi: 10.3390/molecules26071987.

*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis.

Front Genet. 2020 Dec 22;11:576046. doi: 10.3389/fgene.2020.576046. eCollection 2020.

Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization: From TSOC ACS-DM registry.

Medicine (Baltimore). 2020 May;99(19):e19969. doi: 10.1097/MD.0000000000019969.

Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor.

Medicine (Baltimore). 2020 Jan;99(4):e18683. doi: 10.1097/MD.0000000000018683.

Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI.

Exp Ther Med. 2018 Oct;16(4):3492-3496. doi: 10.3892/etm.2018.6650. Epub 2018 Aug 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献